哪里想瘦打哪里！FDA批准Kythera施用药物上市在即

你才双下巴，你全家都双下巴！只不过小姑娘不免人皆有之。如果说赘肉是每一个决心拥有完美身材的“妹纸”或“汉纸”的迷乱，那么一个喜感十足的双下巴称得上是这些人的生死仇敌了。每一分钟，国外都有人为自己的一张大饼脸而感到烦恼，虽然拥有一个肉感十足的双下巴捏上去是不下有肉感的，但是还是有很多人的身体素质使其只能施加一个双下巴之重。您可千万别叹，这甚至现在转变成一个庞大的市场竞争。根据美国眼部外科手术协会的追查研究显示，68%的英裔对自己的双下巴表示了“厌倦”之情。而正因如此，最近Kythera的公司向FDA提交了其专门消灭双下巴的按摩注射型式类固醇ATX-101。这种类固醇完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，称得上是定时健美。不要以为这种正因如此任性的类固醇只是一个叹话，在FDA其下属的眼部和神经外科类固醇专员会的无记名投票中所，专家可是以17：0的超高投票率一致赞许其纳斯达克。或许是因为这些专家中所也有很多饱受双下巴之苦吧。FDA也将蓝图于当年的5年底13日以后对其作出最后决定。如果一切顺利的话，Kythera的公司蓝图于当年下半年将该新产品纳斯达克，分析社会大众预期这一类固醇的产值将超过3亿美元之多。随着按摩类固醇市场竞争的日益增大，Kythera的公司称得上是下了一步好棋。的公司于去年以8400万美元的价格比从其前合作伙伴拜耳控制权所收回了这种类固醇的全部公民权。而Kythera的公司也决心为了将为后所在按摩类固醇市场竞争中所固守拔寨。就在上个年底，Kythera的公司和Actelion的公司达成价值2700万美元的合作协议，共同开发一种失败过的炎炎症类固醇，而这种类固醇被相信有可能开发出一种治疗脱发的类固醇。简要英文报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.